4.6 Article

E-Cadherin Loss Accelerates Tumor Progression and Metastasis in a Mouse Model of Lung Adenocarcinoma

Journal

Publisher

AMER THORACIC SOC
DOI: 10.1165/rcmb.2017-0210OC

Keywords

E-cadherin; Kras; metastasis; non-small cell lung cancer; p53

Funding

  1. American Cancer Society Postdoctoral Fellowship [PF-09-121-01-DDC]
  2. Harvard Stem Cell Institute National Institutes of Health (NIH) training grant
  3. Free to Breathe
  4. V Foundation for Cancer Research
  5. American Cancer Society Research Scholar grant [RSG-08-082-01-MGO]
  6. Freeman Trust
  7. Harvard Stem Cell Institute
  8. NIH/National Heart, Lung, and Blood Institute [R01 HL090136, R01 HL132266, R01 HL125821, U01 HL100402, RFA-HL-09-004]
  9. Thoracic Foundation
  10. Ellison Foundation
  11. Joan's Legacy
  12. Boston Children's Hospital Faculty Career Development Fellowship

Ask authors/readers for more resources

Metastatic disease is the primary cause of death of patients with lung cancer, but the mouse models of lung adenocarcinoma do not accurately recapitulate the tumor microenvironment or metastatic disease observed in patients. In this study, we conditionally deleted E-cadherin in an autochthonous lung adenocarcinoma mouse model driven by activated oncogenic Kras and p53 loss. Loss of E-cadherin significantly accelerated lung adenocarcinoma progression and decreased survival of the mice. Kras;p53;E-cadherin mice had a 41% lung tumor burden, invasive grade 4 tumors, and a desmoplastic stroma just 8 weeks after tumor initiation. One hundred percent of the mice developed local metastases to the lymph nodes or chest wall, and 38% developed distant metastases to the liver or kidney. Lung adenocarcinoma cancer cell lines derived from these tumors also had high migratory rates. These studies demonstrate that the Kras;p53;E-cadherin mouse model better emulates the tumor microenvironment and metastases observed in patients with lung adenocarcinoma than previous models and may therefore be useful for studying metastasis and testing new lung cancer treatments in vivo.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available